The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Malignant hyperthermia
Open accessAbstract
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anesthetic gases such as halothane, sevoflurane, desflurane and the depolarizing muscle relaxant succinylcholine, and rarely, in humans, to stresses such as vigorous exercise and heat. The incidence of MH reactions ranges from 1:5,000 to 1:50,000-100,000 anesthesias. However, the prevalence of the genetic abnormalities may be as great as one in 3,000 individuals. MH affects humans, certain pig breeds, dogs, horses, and probably other animals. The classic signs of MH include hyperthermia to marked degree, tachycardia, tachypnea, increased carbon dioxide production, increased oxygen consumption, acidosis, muscle rigidity, and rhabdomyolysis, all related to a hypermetabolic response. The syndrome is likely to be fatal if untreated. Early recognition of the signs of MH, specifically elevation of end-expired carbon dioxide, provides the clinical diagnostic clues. In humans the syndrome is inherited in autosomal dominant pattern, while in pigs in autosomal recessive. The pathophysiologic changes of MH are due to uncontrolled rise of myoplasmic calcium, which activates biochemical processes related to muscle activation. Due to ATP depletion, the muscle membrane integrity is compromised leading to hyperkalemia and rhabdomyolysis. In most cases, the syndrome is caused by a defect in the ryanodine receptor. Over 90 mutations have been identified in the RYR-1 gene located on chromosome 19q13.1, and at least 25 are causal for MH. Diagnostic testing relies on assessing the in vitro contracture response of biopsied muscle to halothane, caffeine, and other drugs. Elucidation of the genetic changes has led to the introduction, on a limited basis so far, of genetic testing for susceptibility to MH. As the sensitivity of genetic testing increases, molecular genetics will be used for identifying those at risk with greater frequency. Dantrolene sodium is a specific antagonist of the pathophysiologic changes of MH and should be available wherever general anesthesia is administered. Thanks to the dramatic progress in understanding the clinical manifestation and pathophysiology of the syndrome, the mortality from MH has dropped from over 80% thirty years ago to less than 5%.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new generation of Ca2+ indicators with greatly improved fluorescence properties.
Grynkiewicz, G., Poenie, M., & Tsien, R. Y. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)83641-4 · Cited by 21,607
Polazzi, E., Mengoni, I., Caprini, M., Peña-Altamira, E., Kurtys, E., & Monti, B. (2013) · Neurosignals · doi:10.1159/000337115 · Cited by 8,994
Neuroleptic Malignant Syndrome
Strawn, J. R., Keck, P. E., & Caroff, S. N. (2007) · American Journal of Psychiatry · doi:10.1176/ajp.2007.164.6.870 · Cited by 579
A Clinical Grading Scale to Predict Malignant Hyperthermia Susceptibility
Larach, M. G., Localio, A. R., Allen, G. C., Denborough, M. A., Ellis, F. R., Gronert, G. A., Kaplan, R. F., Muldoon, S. M., Nelson, T. E., Ørding, H., et al. (1994) · Anesthesiology · doi:10.1097/00000542-199404000-00008 · Cited by 572
Self-citationMutations in RYR1 in malignant hyperthermia and central core disease
Robinson, R., Carpenter, D., Shaw, M.-A., Halsall, J., & Hopkins, P. (2006) · Human Mutation · doi:10.1002/humu.20356 · Cited by 502
Monnier, N., Procaccio, V., Stieglitz, P., & Lunardi, J. (1997) · The American Journal of Human Genetics · doi:10.1086/515454 · Cited by 420
Localization of the malignant hyperthermia susceptibility locus to human chromosome 19ql2–13.2
McCarthy, T. V., Healy, J. M. S., Heffron, J. J. A., Lehane, M., Deufel, T., Lehmann-Horn, F., Farrall, M., & Johnson, K. (1990) · Nature · doi:10.1038/343562a0 · Cited by 368
Ryanodine receptor mutations in malignant hyperthermia and central core disease
McCarthy, T. V., Quane, K. A., & Lynch, P. J. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200005)15:5<410::aid-humu2>3.0.co;2-d · Cited by 339
ØRDING, H., BRANCADORO, V., COZZOLINO, S., ELLIS, F. R., GLAUBER, V., GONANO, E. F., HALSALL, P. J., HARTUNG, E., HEFFRON, J. J. A., HEYTENS, L., et al. (1997) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.1997.tb04820.x · Cited by 294
Larach, M. G. (1989) · PubMed · Cited by 286
Cited by
Physiological roles of hydrogen sulfide in mammalian cells, tissues, and organs
Cirino, G., Szabo, C., & Papapetropoulos, A. (2023) · Physiological Reviews · doi:10.1152/physrev.00028.2021 · Cited by 553
New functions of mitochondria associated membranes in cellular signaling
van Vliet, A. R., Verfaillie, T., & Agostinis, P. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.03.009 · Cited by 353
Thermoregulatory disorders and illness related to heat and cold stress
Cheshire, W. P. (2016) · Autonomic Neuroscience · doi:10.1016/j.autneu.2016.01.001 · Cited by 349
Brain–heart interactions: physiology and clinical implications
Silvani, A., Calandra-Buonaura, G., Dampney, R. A. L., & Cortelli, P. (2016) · Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences · doi:10.1098/rsta.2015.0181 · Cited by 302
Ryanodine Receptors: Structure and Function
Van Petegem, F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.r112.349068 · Cited by 291
Metadata
- Authors
- Rosenberg, H., Davis, M., James, D., Pollock, N., & Stowell, K.
- Venue
- Orphanet Journal of Rare Diseases
- Published
- 2007-04-24
- Volume
- 2
- Issue
- 1
- Pages
- 21-21
- ISSN
- 1750-1172 (ISSN-L)
- OpenAlex
- W4211223349
- Cited by
- 393
- References
- 54
- FWCI
- 22.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Malignant hyperthermia. https://app.cochat.ai/papers/10.1186/1750-1172-2-21
- The paper
- Rosenberg, H., Davis, M., James, D., Pollock, N., & Stowell, K. (2007). Malignant hyperthermia. Orphanet Journal of Rare Diseases. https://doi.org/10.1186/1750-1172-2-21
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.